Novartis Looks To Expand Beovu’s Use And Move On From Safety Scare

Diabetic Macular Edema (DME) Filing Possible In 2021

 
• By Andrew McConaghie
  
Basel, Switzerland - 27 August, 2016: sign on the wall of a Novartis building. Novartis International AG is a Swiss pharmaceutical company based in Basel, Switzerland.
Forecasts for Beovu have been downgraded after the safety concerns emerged in February

More from Clinical Trials

More from R&D